Summit shares fall following lung cancer drug trial results for Ivonescimab

3 hours ago 1

Summit Therapeutics (NASDAQ:SMMT) on Sunday announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab.
Ivonescimab combined with chemotherapy showed a trend toward improved overall survival in Western patients with non-small cell lung